Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Squamous Cell Carcinoma of Head and Neck 4 Lung Neoplasms 3 Melanoma 2 Head and Neck Neoplasms 2 Carcinoma, Hepatocellular 2 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Squamous Intraepithelial Lesions 1 Skin Neoplasms 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1 Rectal Neoplasms 1 Prostate Adenocarcinoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Papillomavirus Infections 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms 1 Neoplasm, Residual 1 Nasopharyngeal Carcinoma 1 Liver Diseases 1 Liposarcoma 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Breast Neoplasms 1

Interventions

Trastuzumab 628 Paclitaxel 577 Cyclophosphamide 555 Docetaxel 485 Capecitabine 402 Letrozole 376 Fulvestrant 327 Doxorubicin 294 Carboplatin 279 Tamoxifen 275 Anastrozole 243 exemestane 228 Radiotherapy 218 Epirubicin 211 Bevacizumab 196 palbociclib 189 pertuzumab 186 Vinorelbine 167 Lapatinib 167 Gemcitabine 166 pembrolizumab 162 Surveys and Questionnaires 139 Exercise 136 Magnetic Resonance Spectroscopy 123 Fluorouracil 119 Blood Specimen Collection 118 eribulin 117 Albumin-Bound Paclitaxel 117 Drug Therapy 111 130-nm albumin-bound paclitaxel 111

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Adjuvants, Pharmaceutic × Clear all

NCT05296746 2026-05-14

RIBOLARIS

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡